Circ Pharma Limited Enters Into Development Agreement for Chrono Tramadol With Elan Corporation Plc
The product incorporates Circ Pharma's proprietary drug delivery technology enabling once daily dosing. Circ's technology provides for minimized delivery to the body during sleeping hours, acceleration of drug absorption immediately prior to the waking hours and the subsequent maintenance of efficacious drug levels for the remainder of the waking hours. Circ has successfully completed Phase I testing on the product. Circ Pharma intends to seek a licensing partner for worldwide commercial distribution of the product.
The agreement with Elan provides that Elan support the continued formulation and manufacturing activities required to seek regulatory approval for this product in the United States and elsewhere.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.